EWTX logo

Edgewise Therapeutics, Inc. (EWTX) Cash From Financing

Annual CFF:

$249.25M+$196.09M(+368.82%)
December 31, 2024

Summary

  • As of today, EWTX annual cash from financing is $249.25 million, with the most recent change of +$196.09 million (+368.82%) on December 31, 2024.
  • During the last 3 years, EWTX annual cash from financing has risen by +$62.87 million (+33.73%).
  • EWTX annual cash from financing is now at all-time high.

Performance

EWTX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEWTXcash flow metrics

Quarterly CFF:

$1.66M-$186.57M(-99.12%)
September 30, 2025

Summary

  • As of today, EWTX quarterly cash from financing is $1.66 million, with the most recent change of -$186.57 million (-99.12%) on September 30, 2025.
  • Over the past year, EWTX quarterly cash from financing has dropped by -$1.67 million (-50.23%).
  • EWTX quarterly cash from financing is now -99.31% below its all-time high of $241.07 million, reached on March 31, 2024.

Performance

EWTX Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEWTXcash flow metrics

TTM CFF:

$195.01M-$1.67M(-0.85%)
September 30, 2025

Summary

  • As of today, EWTX TTM cash from financing is $195.01 million, with the most recent change of -$1.67 million (-0.85%) on September 30, 2025.
  • Over the past year, EWTX TTM cash from financing has dropped by -$104.34 million (-34.86%).
  • EWTX TTM cash from financing is now -34.86% below its all-time high of $299.35 million, reached on September 30, 2024.

Performance

EWTX TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherEWTXcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

EWTX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+368.8%-50.2%-34.9%
3Y3 Years+33.7%-98.7%+49.7%
5Y5 Years+905.0%--

EWTX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high+368.8%-99.3%+590.8%-34.9%>+9999.0%
5Y5-Yearat high+905.0%-99.3%+285.2%-34.9%>+9999.0%
All-TimeAll-Timeat high+905.0%-99.3%+285.2%-34.9%>+9999.0%

EWTX Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
$1.66M(-99.1%)
$195.01M(-0.9%)
Jun 2025
-
$188.23M(+8367.4%)
$196.68M(+1790.6%)
Mar 2025
-
$2.22M(-23.2%)
$10.40M(-95.8%)
Dec 2024
$249.25M(+368.8%)
$2.90M(-13.1%)
$249.25M(-16.7%)
Sep 2024
-
$3.33M(+70.7%)
$299.35M(+1.2%)
Jun 2024
-
$1.95M(-99.2%)
$295.80M(+0.5%)
Mar 2024
-
$241.07M(+355.0%)
$294.22M(+453.4%)
Dec 2023
$53.17M(-59.0%)
$52.99M(>+9900.0%)
$53.17M(>+9900.0%)
Sep 2023
-
-$211.00K(-157.2%)
-$159.00K(-100.1%)
Jun 2023
-
$369.00K(+1657.1%)
$129.78M(+0.1%)
Mar 2023
-
$21.00K(+106.2%)
$129.59M(-0.0%)
DateAnnualQuarterlyTTM
Dec 2022
$129.64M(-30.4%)
-$338.00K(-100.3%)
$129.64M(-0.5%)
Sep 2022
-
$129.72M(>+9900.0%)
$130.27M(>+9900.0%)
Jun 2022
-
$179.00K(+145.2%)
$582.00K(+218.1%)
Mar 2022
-
$73.00K(-75.1%)
-$493.00K(-100.3%)
Dec 2021
$186.38M(+55.0%)
$293.00K(+691.9%)
$186.38M(+0.2%)
Sep 2021
-
$37.00K(+104.1%)
$186.09M(+0.0%)
Jun 2021
-
-$896.00K(-100.5%)
$186.05M(-0.6%)
Mar 2021
-
$186.95M(>+9900.0%)
$187.09M(>+9900.0%)
Dec 2020
$120.28M(+385.0%)
-
-
Jun 2020
-
$135.00K(>+9900.0%)
$135.00K(>+9900.0%)
Mar 2020
-
$0.00
$0.00
Dec 2019
$24.80M
-
-

FAQ

  • What is Edgewise Therapeutics, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Edgewise Therapeutics, Inc.?
  • What is Edgewise Therapeutics, Inc. annual cash from financing year-on-year change?
  • What is Edgewise Therapeutics, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Edgewise Therapeutics, Inc.?
  • What is Edgewise Therapeutics, Inc. quarterly cash from financing year-on-year change?
  • What is Edgewise Therapeutics, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Edgewise Therapeutics, Inc.?
  • What is Edgewise Therapeutics, Inc. TTM cash from financing year-on-year change?

What is Edgewise Therapeutics, Inc. annual cash from financing?

The current annual cash from financing of EWTX is $249.25M

What is the all-time high annual cash from financing for Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. all-time high annual cash from financing is $249.25M

What is Edgewise Therapeutics, Inc. annual cash from financing year-on-year change?

Over the past year, EWTX annual cash from financing has changed by +$196.09M (+368.82%)

What is Edgewise Therapeutics, Inc. quarterly cash from financing?

The current quarterly cash from financing of EWTX is $1.66M

What is the all-time high quarterly cash from financing for Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. all-time high quarterly cash from financing is $241.07M

What is Edgewise Therapeutics, Inc. quarterly cash from financing year-on-year change?

Over the past year, EWTX quarterly cash from financing has changed by -$1.67M (-50.23%)

What is Edgewise Therapeutics, Inc. TTM cash from financing?

The current TTM cash from financing of EWTX is $195.01M

What is the all-time high TTM cash from financing for Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. all-time high TTM cash from financing is $299.35M

What is Edgewise Therapeutics, Inc. TTM cash from financing year-on-year change?

Over the past year, EWTX TTM cash from financing has changed by -$104.34M (-34.86%)
On this page